Navigation Links
Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
Date:10/6/2008

ubject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of

operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
2. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
3. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
6. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. The Childrens Hospital of Philadelphia Announces New Regional Participant in The National Childrens Study
9. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
10. Resurgent Health and Medical Announces That Childrens Hospitals and Clinics of Minnesota has Ordered 25 CleanTech Automated Handwashing Systems
11. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015  Verus Healthcare, Inc. ... acquisition of CPAP Care Club in 2012.  Since that ... within the durable medical equipment (DME) industry by 1,000%.  ... for their CPAP supply needs and processes nearly 14,000 ... this company three years ago, the systems and processes ...
(Date:5/4/2015)... , May 4, 2015 ... Market by Scope (Rigid (Laparoscope, Ureteroscope), Flexible (Colonoscope, Gastroscope), ... by Application (Colonoscopy, Laparoscopy, Arthroscopy) - Global Forecasts to ... expected to reach $19.0 Billion by 2019 with a ... to 2019). Browse   127   ...
(Date:5/4/2015)... 2015 /PRNewswire/ - YOLO Medical Inc. , ... distribution of medical and aesthetic devices, proudly announces ... YOLO,s new generation body contouring laser system; LIPOFINA. ... second-generation low-level laser device for body contouring, creating ... patented technology while continuing to push the envelope ...
Breaking Medicine Technology:Verus Healthcare Celebrates 1,000% Growth on Third Anniversary 2The Medical Videoscope Market Worth $19.0 Billion by 2019 2The Medical Videoscope Market Worth $19.0 Billion by 2019 3The Medical Videoscope Market Worth $19.0 Billion by 2019 4The Medical Videoscope Market Worth $19.0 Billion by 2019 5YOLO Medical Inc. receives FDA clearance for body contouring laser 2
... 2011 Reportlinker.com announces that a new ... its catalogue: Immunotherapy ... http://www.reportlinker.com/p0284906/Immunotherapy-in-Oncology-Drug-Pipeline-Update-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy ... attractive therapeutic addition, delivering treatment of ...
... Scotland, September 7, 2011 The Astellas European ... Transplantation Grant: Dr Christian Toso of the University ... led by Dr Toso, received the grant of US$ 300,000 ... tailored immuno - suppression after liver transplantation for ...
Cached Medicine Technology:Immunotherapy in Oncology Drug Pipeline Update 2011 2Immunotherapy in Oncology Drug Pipeline Update 2011 3Immunotherapy in Oncology Drug Pipeline Update 2011 4Immunotherapy in Oncology Drug Pipeline Update 2011 5Immunotherapy in Oncology Drug Pipeline Update 2011 6Immunotherapy in Oncology Drug Pipeline Update 2011 7The Astellas European Foundation Winner of Transplantation Grant 2011 Announced 2
(Date:5/4/2015)... 2015 New findings released today from ... (ABTA) show that people diagnosed with a brain tumor ... including clinical trials, at the time of diagnosis, and ... decisions about their course of treatment. The release of ... nationwide brain tumor volunteer network, the ABTA CommYOUnity™, dedicated ...
(Date:5/4/2015)... 2015 Dr. Benjamin Stong of Kalos ... the latest non-surgical double-chin eliminator. Dr. Stong is ... in Atlanta to offer Kybella treatments . The ... specifically under the chin, promising to safely dissolve fat ... patients who sought immediate solutions for their double chin ...
(Date:5/4/2015)... May 04, 2015 In response ... Preventive Services Task Force (USPSTF), Strategic Radiology® (SR®) ... Congress of Obstetricians and Gynecologists (ACOG), the American ... Cure, American Cancer Society (ACS), American College of ... to unanimously recommend regular screening mammography for women ...
(Date:5/4/2015)... “ Food Cost Calculator ” was featured on NewsWatch ... at the latest and coolest applications on the market for ... and technology expert, conducted the app review and shared with ... efficiently calculate food costs. , The restaurant industry is a ... has an estimated 1.8 trillion dollar impact on the US ...
(Date:5/4/2015)... San Diego, CA (PRWEB) May 04, 2015 ... New Cireson Platform to ... Cireson offers customers a choice to consume Microsoft ... cloud or Hyper-V on premise , Company ... focused model , Continuous innovation with expanding ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 2Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 3Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 4Health News:Strategic Radiology® Takes Unified Stance Against New USPSTF Guidelines 5Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 3Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 4
... 4 Crdentia Corp. (OTC Bulletin,Board: CRDT), ... services,today announced the appointment of Mr. Randall ... Chief Clinical Officer. In this newly created,position, ... compliance and accreditation, assisting in business,plan development ...
... Online Resource to Support Journal Editors Handling ... of scientific, technical and,medical information products and ... Ethics Resource Kit (PERK),( http://www.elsevier.com/publishingethicskit )., ... in Singapore, Mark,Seeley, Senior Vice President and ...
... 4 Seniors have done their share.,Millions stepped ... insurance and state government have failed to stop,runaway ... rich coverage have,been forced to lapse their policies. ... approval and endorsement., Last week,s Wall Street ...
... nutrient education, WHITE PLAINS, N.Y., March 4 Despite ... to take drastic measures to lose,weight, with one third saying ... lose a few pounds, a recent survey found., Although ... of the time or more often, many do not fully ...
... report they are not getting the sleep they need ... may contribute to their inadequate sleep. The survey, issued ... (ACCP-SI), found that most physicians sleep fewer hours than ... believe their work schedules do not allow for adequate ...
... cellular pathways involved in cancer metastasis , , MONDAY, March ... regulates development of human embryonic stem cells can inhibit ... breast cancers, says a study by researchers at Northwestern ... week,s online issue of the Proceedings of the ...
Cached Medicine News:Health News:Crdentia Appoints Randall Turnbull to Senior Vice President and Chief Clinical Officer 2Health News:Crdentia Appoints Randall Turnbull to Senior Vice President and Chief Clinical Officer 3Health News:Elsevier Launches Publishing Ethics Resource Kit 2Health News:State Governments are Snookering Seniors 2Health News:New Survey Shows 90 Percent of Women Do Not Fully Understand the Calories They Eat 2Health News:New Survey Shows 90 Percent of Women Do Not Fully Understand the Calories They Eat 3Health News:Physicians report they need more sleep 2Health News:Physicians report they need more sleep 3Health News:Embryonic Stem Cell Protein Inhibits Melanoma 2
... Flexible Ureteroscope (DUR-D) incorporates many of ... durable, market leading DUR® series flexible ... device utilizing Gyrus ACMIs proprietary, worlds ... Oxide Semi-Conductor (CMOS) distal sensor technology ...
... new ImmunoCard STAT! EHEC is the first one-step ... Shiga Toxin 1 and 2 produced by Enterohemorrhagic ... on McConkey broth overnight enrichment of fecal specimens ... and 100% specificity., The separate result for Toxin ...
Inquire...
... elegant and sophisticated woman, the ... ophthalmic and sunwear styles. Frames ... of shapes and colors, designed ... and complexions. Many styles feature ...
Medicine Products: